Processa Pharmaceuticals, Inc. — Director's Dealing 2021

Jul 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2021-07-08

Reporting Person: Floyd Robert Michael (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-08	Restricted Stock Units	$0	A	8572	Acquired		Common Stock (8572)	Direct
2021-07-08	Restricted Stock Units	$0	A	12858	Acquired		Common Stock (12858)	Direct
2021-07-08	Restricted Stock Units	$0	A	1907	Acquired		Common Stock (10034)	Direct

Footnotes

F1: The restricted stock units vest in two equal installments beginning July 1, 2022.

F2: The Restricted Stock Units vest upon achievement of certain performance goals.

F3: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.